000283065 001__ 283065
000283065 005__ 20251230103620.0
000283065 0247_ $$2doi$$a10.1002/alz70857_100294
000283065 0247_ $$2pmid$$apmid:41446930
000283065 0247_ $$2pmc$$apmc:PMC12739507
000283065 0247_ $$2ISSN$$a1552-5260
000283065 0247_ $$2ISSN$$a1552-5279
000283065 037__ $$aDZNE-2025-01472
000283065 041__ $$aEnglish
000283065 082__ $$a610
000283065 1001_ $$aTegethoff, Paulina$$b0
000283065 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283065 245__ $$aMotivation, Worries and Digital Affinity in Alzheimer's Disease Research ‐ Qualitative Findings from Davos Alzheimer's Collaborative
000283065 260__ $$c2025
000283065 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767013572_31207
000283065 3367_ $$033$$2EndNote$$aConference Paper
000283065 3367_ $$2BibTeX$$aINPROCEEDINGS
000283065 3367_ $$2DRIVER$$aconferenceObject
000283065 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283065 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283065 3367_ $$2ORCID$$aOTHER
000283065 520__ $$aSubjective cognitive deficits are the earliest clinical sign of Alzheimer's disease (AD), raising interest in early detection when disease-modifying drugs promise the greatest benefit. The CogScreen 1 and 2 studies, part of the Davos Alzheimer's Collaborative's Healthcare Systems Preparedness program, evaluate tools for community-based screening for AD in the earliest clinical stages. During the studies, a systematic investigation of participant motivations, concerns, and suggestions for trial improvement emerged as essential.A qualitative interview guide was developed and applied in 30 telephone interviews with randomly assigned former participants. Recorded and transcribed data were analyzed using the MAXQDA software (VERBI Software), employing an inductive-deductive coding guide. Thematic content analysis identified key patterns and insights into the motivation, concerns and digital affinity of participants in an AD research study.The study uncovered valuable perspective on Alzheimer´s research. Participants revealed diverse motivations for involvement, ranging from personal connections to dementia to aspirations for early diagnosis and treatment. Reactions to potential diagnoses ranged from shock and grief to proactive care strategies. Digital affinity varied but showed encouraging levels of familiarity with technology among older adults. Participants raised concerns about the study design, including item clarity and response scales, as well as suggestions for improving digital and traditional tools.By systematically capturing participant feedback, the CogScreen study provides critical insights for improving AD research methodologies, particularly in relation to the participatory nature of research. These findings underline the importance of addressing participants' motivations and fears while integrating innovative tools. The results also highlight the feasibility of digital interventions in ageing populations and emphasize trust in public institutions. Future studies should use these findings to refine early detection approaches and encourage greater participant engagement.
000283065 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283065 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283065 650_2 $$2MeSH$$aHumans
000283065 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000283065 650_2 $$2MeSH$$aAlzheimer Disease: psychology
000283065 650_2 $$2MeSH$$aMale
000283065 650_2 $$2MeSH$$aFemale
000283065 650_2 $$2MeSH$$aAged
000283065 650_2 $$2MeSH$$aMotivation
000283065 650_2 $$2MeSH$$aAged, 80 and over
000283065 650_2 $$2MeSH$$aMiddle Aged
000283065 650_2 $$2MeSH$$aQualitative Research
000283065 650_2 $$2MeSH$$aInterviews as Topic
000283065 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000283065 7001_ $$aKurz, Carolin Isabella$$b1
000283065 7001_ $$0P:(DE-2719)9003081$$aHufnagel, Anna$$b2$$udzne
000283065 7001_ $$aRutt, Sophia$$b3
000283065 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b4$$eLast author$$udzne
000283065 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70857_100294$$gVol. 21 Suppl 3, no. Suppl 3, p. e100294$$nSuppl 3$$pe100294$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283065 8564_ $$uhttps://pub.dzne.de/record/283065/files/DZNE-2025-1472.pdf$$yOpenAccess
000283065 8564_ $$uhttps://pub.dzne.de/record/283065/files/DZNE-2025-1472.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283065 909CO $$ooai:pub.dzne.de:283065$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000283065 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003081$$aExternal Institute$$b2$$kExtern
000283065 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000283065 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283065 9141_ $$y2025
000283065 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283065 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283065 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000283065 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283065 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283065 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283065 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283065 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283065 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000283065 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283065 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283065 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283065 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x0
000283065 980__ $$aabstract
000283065 980__ $$aVDB
000283065 980__ $$aUNRESTRICTED
000283065 980__ $$ajournal
000283065 980__ $$aI:(DE-2719)5000022
000283065 9801_ $$aFullTexts